Key Highlights
- Dr. Yooni Kim appointed Managing Director for APAC effective September 1, 2024.
- Dr. Kim brings over 25 years of clinical research leadership experience to the role.
- Strategic appointment aligns with Novotech’s expansion in global clinical trials.
- Novotech continues strengthening its presence across Asia-Pacific.
Source: Business Wire
Notable Quotes
- “Her deep understanding of the clinical research landscape in Asia, how this integrates into the global clinical research environment, and her leadership skills, will be invaluable as we continue to expand and strengthen our presence in this critical region.” — Dr. John Moller, CEO at Novotech
- “I bring a strategic approach to make growing Novotech’s capabilities stronger in the region. I will prioritize the needs of customers and deliver exceptional value and service.” — Dr. Yooni Kim, Managing Director APAC at Novotech
SoHC's Take
This appointment is a strategic move by Novotech, signaling the company’s strong commitment to furthering its global reach while deepening its focus on the Asia-Pacific region. Dr. Yooni Kim’s extensive background in clinical research and proven leadership within the industry will be key to driving the company’s growth and enhancing its operational excellence across this critical market. Novotech’s leadership in aligning local and global strategies will help solidify its status as a world-class partner in biotech clinical trials.
